Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Incepta Pharmaceuticals Ltd.

Home Clinical Trial Sponsors and OrganizationsIncepta Pharmaceuticals Ltd.

Incepta Pharmaceuticals Ltd.

ACTIVE

Bangladeshwww.inceptapharma.comPrivate5,001–10,000 employeesEstablished: 1999-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

12

5 active

Approvals

2

Total approvals

Agencies

2

Regulatory bodies

Founded

1999

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

4

33.3%

Phase 1

2

16.7%

Phase 2

1

8.3%

Trial Status Distribution

Completed

5

41.7%

Not yet recruiting

5

41.7%

Recruiting

1

8.3%

Unknown

1

8.3%

Clinical Trials

Trials sponsored by this organization (12)

A Single Dose Two Period Study Comparing Gabapentin Tablets 300 Mg In Healthy Adult Human Subjects Under Fed Conditions

Not yet recruiting

Feb 202640 participants

An Open Label Single Dose Four Period Oral Bioequivalence Study Comparing Mesalamine Delayed-Release Tablets 1.2g In Healthy Adult Human Subjects Under Fed Conditions

Not yet recruiting

Jan 202616 participants

An Open Label Single Dose Two Period Oral Bioequivalence Design In Healthy Adult Human Subjects Under Fed Conditions

Not yet recruiting

Nov 202540 participants

PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).

Apr 202556 participants

An Open Label Single Dose Two Treatment Three Period Partial Replicate Reference scaled Oral Bioequivalence Study Comparing Valsartan and Hydrochlorothiazide Tablets In Healthy Adult Human Subjects Under Fasting Conditions

Mar 202560 participants

An Open Label Single Dose Two Treatment Two Period Two Way Crossover Oral Bioequivalence Study Comparing Valsartan/Hydrochlorothiazide Tablets USP 320 mg/25 mg In Healthy Adult Human Subjects Under Fasting Conditions

Not yet recruiting

Feb 202516 participants

A Study to Evaluate the Safety and immunogenicity of Pegylated Erythropoietin 100 mcg/0.3 ml injection (PEG-EPO)

Jan 2025126 participants

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Mar 202470 participants

Page 1 of 2

Approvals

Approvals by Agency

PHILIPPINES

Philippines FDA

1

Approvals

NPRA

National Pharmaceutical Regulatory Agency

1

Approvals

Recent Approvals

UNIQUIN (Hydroxychloroquine Sulfate 200mg Film Coated Tablet)

News

No news articles found

On this page

Overview
Clinical Trials12
Approvals2
News

Back to Organizations